Elicio Therapeutics, Inc. (ELTX) — 10-Q Filings
All 10-Q filings from Elicio Therapeutics, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Elicio Narrows Losses, Boosts Cash Amid R&D Spend Cuts
— Nov 13, 2025 Risk: high
Elicio Therapeutics, Inc. (ELTX) reported a net loss of $10.083 million for the three months ended September 30, 2025, a significant improvement from the $18.83 -
Elicio Therapeutics Reports No Revenue, Continues R&D Spend
— Aug 7, 2025 Risk: high
Elicio Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company's net loss -
Elicio Therapeutics Files Q1 2025 10-Q
— May 13, 2025 Risk: low
Elicio Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Angion Biomedica Corp., is in the pharmaceutical p - 10-Q Filing — Nov 13, 2024
-
Elicio Therapeutics Files Q2 2024 10-Q
— Aug 13, 2024 Risk: medium
Elicio Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Angion Biomedica Corp., is focused on pharmaceutica - 10-Q Filing — May 15, 2024
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX